Adempas

Perhaps folks can type slower so everyone can understand. R e p s - a r e - b e i n g - l e t - g o

 

O K T H E N!
NOW U S S L O W ONES KNOW W H A T THE H E L L Y O U Meant ! !

 

Boo Hoo, Whaaaaa!

You are given much
Much is expected

Salaries average $130,000+ with big bonus for the reps. I don't feel bad for you at all.

 

Wow that was quick - how long before Merck takes over. May not be such a bad thing

 

What?

 

Merck just bought the entire class of drugs from bayer including Adempas. Don't kid yourself, they will swoop in at the first sign of trouble. And that happened at the start of the hiring process.

 

Merck pays $1B to buy into Bayer's cardio future

May 6, 2014 | By Damian Garde
SHARE





TOOLS
Comment
Print
Contact Author
Reprint
Merck ($MRK) plans to use the proceeds of its planned $14.2 billion consumer business sale to Bayer to beef up its pipeline, and the in-transition pharma giant isn't wasting any time, signing a billion-dollar deal with its new partner in a move to get its hands on some new cardiovascular drugs.

Under the agreement, Merck will hand over $1 billion up front to split the rights to Bayer's stable of drugs that modulate soluble guanylate cyclase (sGC), an enzyme tied to the widening of blood vessels. That includes ex-U.S. rights to Adempas, Bayer's FDA-approved treatment for pulmonary arterial hypertension, and stateside rights to vericiguat, a Phase II sGC modulator under development for worsening heart failure. Merck is on the line for another $1.1 billion in milestone payments tied to collective sales of the whole franchise, Bayer said.

Merck also gets opt-in rights on the rest of Bayer's early-stage sGC drugs and has agreed to make its similar candidates available under the same terms. The two plan to share costs and profits on all co-developed treatments along the way.



Read more: Merck pays $1B to buy into Bayer's cardio future - FierceBiotech http://www.fiercebiotech.com/story/merck-pays-1b-buy-bayers-cardio-future/2014-05-06#ixzz31Xq8cRoQ
Subscribe at FierceBiotech

 

Learn to read: "ex-US rights to Adempas" - that's OUTSIDE the US. The current US Bayer reps are doing just fine. - signed, your competition

 

Looks pretty straightforward - Merck wrote a check for $1B...they call the shots. They WILL make decisions that impact the US business...they have a huge CV sales force

 

Ex-US rights does not refer to "outside the US " it means ex as in previous US rights. Such as ex-patriot.
Sorry...

 

You sir are wrong.

Ex-US in terms of the contract means outside the US. Source: I am a lawyer and read the contract.

 

Sure you are, and you hang out on cafepharma because you're employed. Lol

 

Yes we are . Getting lots of scripts and making lots of $$$ teaching my nurse's kid soccer ?

 

Get back to us after 1Q when the sales plan changes.... Then let us know how lucrative Adempas is to sell. You'll be lucky if you're making $5K / quarter.

 

Things are Great at Adempas.
Sales plan is fine through Q1.

The sales force of 60 recently had 20 resignations mostly to Intermune, a couple to Keryx and 1 or 2 other companies.
The Head of the Business Unit resigned last week too. Good thing there are hundreds of PH patients in Puerto Rico!

Merck will take good care of the remaining team next year.

 

No one is using it. Time to look for another job. Management is all looking for other jobs

 

Did JM leave?

 

Think again...

Cardiopulmonary is the most successful franchise at Bayer with enrollments at an all time high right now!! Sorry you missed the boat or left for Intermune with your IC problems

 

In all seriousness, Bayer is probably the best place to be in PH. Docs are interested in hearing what you have to say. That will change when PO prostacyclin s come out but now it's a fun place to be. Yes about 16 reps left for Intermune but they were giving out awesome packages (120k) to lure away Bayer reps.

 

You must be one of the Bayer reps that ran away because you didn't perform. Half of this team is in the 250-300 range for 2014. Stop being angry bec